Pulmonary Pharmacology & Therapeutics

Items from 1 to 10 out of 10 results

article

Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics

M. Tonelli, M. Zingoni, E. Bacci, F.L. Dente, more

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 237-240

In a single blind study, the short-term efficacy of the addition of leukotriene receptor antagonists (LTRA: montelukast 10 mg o.d. in 15 subjects, zafirlukast 20 mg b.i.d. in 11 subjects) to the current therapy was evaluated in severe asthmatics, unstable under regular treatment with high dose inhaled corticosteroids, bronchodilators and, in seven of them, oral corticosteroids. Each subject monitored...

article

Elastase-induced changes in lung function: relationship to morphometry and effect of drugs

Y. Nishi, V. Boswell, T. Ansari, F. Piprawala, more

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 221-229

Intratracheal administration of porcine pancreatic elastase (PPE) produced a dose related decline in lung function, as assessed by changes in dynamic lung compliance (C _d _y _n ) in New Zealand White rabbits. This occured within 24 h of administration and persisted for 56 days (n=6). These lung function changes were accompanied by histological evidence of emphysema in the lungs and were...

article

Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment

C. Bruschi, P. Crotti, E. Dacosto, F. Fanfulla, more

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 231-236

To evaluate whether the peripherally acting antitussive levodropropizine could affect the respiratory drive and the breathing pattern, we performed a double-blind, randomised, cross-over trial in 12 healthy volunteers and 12 patients with chronic respiratory impairment associated with chronic obstructive pulmonary disease.Levodropropizine 6% drops (at the recommended dose for adults) or placebo were...

article

Inhibition of experimental acute pulmonary inflammation by pirfenidone

J. Spond, N. Case, R.W. Chapman, Y. Crawley, more

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 207-214

Pirfenidone, a putative tumor necrosis factor-α (TNF-α) inhibitor, has recently gained recognition for its therapeutic use in the treatment of idiopathic pulmonary fibrosis. As pulmonary fibrosis may be the result of lung inflammatory processes, we examined the anti-inflammatory potential of pirfenidone in several models of acute pulmonary inflammation. In antigen-induced allergic paradigms, 24 h...

article

Editorial Board

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > CO2

article

Cough sensitivity in atopic dermatitis

R. Pecova, Z. Frlickova, J. Pec, M. Tatar

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 203-206

The aim of study was to investigate the cough sensitivity (C2) to capsaicin (CAPS) in patients with atopic dermatitis without clinical respiratory symptoms. Cough sensitivity (C2) is defined as the lowest CAPS concentration, which evokes two or more coughs.Forty eight dermatological patients (21 M, 27 F; mean age 44 yr) and 24 healthy volunteers (14 M, 10 F; mean age 37 yr) inhaled deep breath (2...

article

Transforming growth factor-β and its role in asthma

Catherine Duvernelle, Véronique Freund, Nelly Frossard

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 181-196

Transforming growth factor-β (TGF-β) is an important fibrogenic and immunomodulatory factor that may play a role in the structural changes observed in the asthmatic airways. In vitro as well as in vivo studies have evidenced a dual role for TGF-β: it can either function as a pro- or anti-inflammatory cytokine on inflammatory cells, participating into the initiation and resultion of inflammatory and...

article

Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophylline

Roberto Walter Dal Negro, Carlo Pomari, Silvia Tognella, Claudio Micheletto

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 241-246

Bronchodilator agents are central to the symptomatic management of Chronic Obstructive Pulmonary Disease (COPD), and long-acting inhaled bronchodilators are regarded as more convenient. The role of inhaled corticosteroids still remains controversial, but there is increasing evidence that they may improve FEV ₁ and symptoms in the long-term.Aim of the present small pilot study was to compare...

article

Long-acting β ₂ agonists as potential option in the treatment of acute exacerbations of COPD

Mario Cazzola, Maria Gabriella Matera

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 197-201

article

Methylprednisolone effects on oxygenation and histology in a rat model of acute lung injury

Chung-Ming Chen, Leng-Fang Wang, Borcherng Su, Hsun-Hui Hsu

Pulmonary Pharmacology & Therapeutics > 2003 > 16 > 4 > 215-220

We examined the effects of methylprednisolone on gas exchange, pressure-volume curve, lavage fluid inflammatory cell counts, protein content, surfactant pool size, and lung histology in a rat model of paraquat-induced lung injury. Twenty-three adult male Sprague-Dawley rats received intraperitoneal paraquat injection (35 mg/kg) and were randomly divided into three groups: (1) control group received...

Filter options

Number:
4
Volume:
16
Year:
2003

Publication date

Set your own date range

Keywords

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (3)
ASTHMA (2)
ACUTE EXACERBATIONS (1)
ACUTE LUNG INJURY (1)
AIRWAYS (1)
ANIMAL MODEL (1)
ATOPIC DERMATITIS (1)
BREATHING PATTERN (1)
BRONCHOALVEOLAR LAVAGE (1)
CAPSAICIN (1)
CHRONIC RESPIRATORY IMPAIRMENT (1)
COMBINATION THERAPY (1)
COPD (1)
COUGH (1)
COUGH SENSITIVITY (1)
EMPHYSEMA (1)
FORMOTEROL (1)
HYPERCAPNIC STIMULUS (1)
IL-6 (1)
INFLAMMATION (1)
INHALED CORTICOSTEROIDS (1)
LABA (1)
LEUKOTRIENES (1)
LEVODROPROPIZINE (1)
LONG-TERM TREATMENT OF (1)
METHYLPREDNISOLONE (1)
MONTELUKAST (1)
P0.1 (1)
PARAQUAT (1)
PIRFENIDONE (1)
PSORIASIS VULGARIS (1)
PULMONARY INFLAMMATION (1)
RABBIT (1)
SALMETEROL (1)
SALMETEROL/FLUTICASONE PROPIONATE (1)
STEREOLOGY (1)
TGF-Β (1)
TNF-Α (1)
ZAFIRLUKAST (1)
more

INFONA - science communication portal

Pulmonary Pharmacology & Therapeutics

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Reporting an error / abuse

Sending the report failed

Accessibility options